Detection of LongR(3)-IGF-I, Des(1-3)-IGF-I, and R-3-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes

Mongongu Cynthia; Coudore Francois; Domergue ValerieEricsson MagnusBuisson CorinneMarchand Alexandre

首页> 外文期刊>Drug testing and analysis >Detection of LongR(3)-IGF-I, Des(1-3)-IGF-I, and R-3-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes

【24h】

Detection of LongR(3)-IGF-I, Des(1-3)-IGF-I, and R-3-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes

机译：Detection of LongR(3)-IGF-I, Des(1-3)-IGF-I, and R-3-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

Insulin-like growth factor-I (IGF-I) and its analogs LongR(3)-IGF-I, Des(1-3)-IGF-I, and R-3-IGF-I are prohibited substances in sport. Although they were never approved for use in humans, they are readily available as black market products for bodybuilding and can be used to enhance physical performance. This study's aims were to validate a fast and sensitive detection method for IGF-I analogs and to evaluate their detectability after intramuscular administration in rats. The sample preparation consisted of an immunopurification on MSIA (TM) microcolumns using a polyclonal anti-human-IGF-I antibody. The target substances were then directly analyzed by nano-liquid chromatography coupled with high-resolution mass spectrometry. Abundant signs of lower quality, oxidized peptide forms were found in black market products, justifying the need to monitor at least both the native and mono-oxidized forms. The analytical performance of this method (linearity, carry over, detection limits, precision, specificity, recovery, and matrix effect) was studied by spiking the analogs into human serum. Following a single intramuscular administration (100 mu g/kg) in rats, detection was evaluated up to 36 h after injection. While unchanged Des(1-3)-IGF-I and R-3-IGF-I were detected until 24 h after administration, LongR(3)-IGF-I disappeared rapidly after 4 h. Des(1)-LongR(3)-IGF-I, a new N-terminal Long-R-3-IGF-I degradation product, was detected in addition to Des(1-10)-LongR(3)-IGF-I and Des(1-11)-LongR(3-)IGF-I: the latter was detected up to 16 h. The same products were found after in vitro incubation of the analogs in human whole blood, suggesting that observations in rats may be extrapolated to humans and that the validated method may be applicable to antidoping testing.

著录项

来源
《Drug testing and analysis》 |2021年第8期|1256-1269|共14页
作者
Mongongu Cynthia; Coudore Francois; Domergue ValerieEricsson MagnusBuisson CorinneMarchand Alexandre;
展开▼
作者单位

AFLD Agence Francaise Lutte Dopage, Dept Anal, Chatenay Malabry, France;

Univ Paris Saclay, INSERM UMRS 1178, Lab Neuropharmacol, Chatenay Malabry, France;

Univ Paris Saclay, Fac Pharm, Plateforme AnimEx IPSIT, AnimEx Chatenay Malabry, Chatenay Malabry;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类药学;
关键词
administration in rat; detection; high resolution mass spectrometry; IGF-I analogs; MSIA;

Detection of LongR(3)-IGF-I, Des(1-3)-IGF-I, and R-3-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes

摘要

著录项

相关主题

期刊订阅